Metabolex Announces Positive Results From its Clinical Study of Arhalofenate ... - PR Newswire (press release)

Metabolex Announces Positive Results From its Clinical Study of Arhalofenate ... PR Newswire (press release) In the US, the goal of treatment is to reduce sUA levels to below 6 mg/dL. However, patients with severe tophaceous gout would benefit from reducing their sUA values below 5 or even 4 mg/dL because this would result in more rapid dissolution of their ... and more »

Savient Pharmaceuticals: The Potential Role Of Krystexxa The Treatment Of Gout - Seeking Alpha

Savient Pharmaceuticals: The Potential Role Of Krystexxa The Treatment Of Gout Seeking Alpha Earlier and milder stages of gout can be treated with diet and exercise. As gout progresses, it is treated with two types of drugs. Pain relievers like the non-steroidal anti-inflammatory drug are used to treat the pain associated with acute flares. ...

New Algorithm Recommends Dosing Adjustments for Gout Treatment - Pain Medicine News

New Algorithm Recommends Dosing Adjustments for Gout Treatment Pain Medicine News They recommended reducing dosages of colchicine by 33% to 66% when treating acute attacks of gout, and by 55% to 75% for prophylactic treatment, except when coadministered with azithromycin, for which no dose adjustment is necessary. ...

Metabolex Gout Program Recognized in Windhover's Top 10 Most Interesting ... - Sacramento Bee

Metabolex Gout Program Recognized in Windhover's Top 10 Most Interesting ... Sacramento Bee Arhalofenate is a potential best-in-class treatment for gout that not only treats the hyperuricemia that causes gout, but also addresses aspects of the metabolic abnormalities that are prevalent amongst patients with gout. Arhalofenate was selected by ... and more »